Skip to main content

Phase 2/3 Neurology Deal Benchmarks

Median Upfront
$536M
Range: $293M - $769M
Total Deal Value
$3.5B
Range: $2.3B - $4.8B
Royalty Rate
14.8% - 22.2%
Tiered up to 26.2%
Dev Milestones
$722M
Range: $483M - $964M

Market Analysis

Phase 2/3 neurology licensing deals carry a median total deal value of $3.5B, with upfront payments ranging from $293M to $769M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 15% to upfront and 85% to milestones.

The neurology landscape at the phase 2/3 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $722M, regulatory milestones contribute $1.1B, and commercial milestones reach $1.2B. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 2/3 neurology deals range from 14.8% to 22.2% at the base tier, with high-tier escalation to 26.2%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 2/3 neurology deals?
Phase 2/3 neurology deals average $536M in upfront payments, ranging from $293M to $769M. The upfront allocation of 15% of total deal value reflects the clinical stage risk profile.
How are phase 2/3 neurology deal milestones structured?
Milestones account for approximately 85% of total deal value. Development milestones ($722M) represent the largest component, followed by commercial milestones ($1.2B) and regulatory milestones ($1.1B).
What royalty rates are typical for phase 2/3 neurology licensing?
Base royalty rates range from 14.8% to 22.2%, with tiered escalation to 18.8%-26.2% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included